Test Id : FFCAH
Congenital Adrenal Hyperplasia (CAH) Pediatric Profile 6, Comprehensive Screen
Method Name
A short description of the method used to perform the test
High Pressure Liquid Chromatography/Tandem Mass Spectrometry (HPLC/MS-MS)
NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test
Aliases
Lists additional common names for a test, as an aid in searching
CAH Profile 6
CAH Profile 6-Comprehensive
Congenital Adrenal Hyperplasia, Comprehensive Screen
Specimen Type
Describes the specimen type validated for testing
Serum Red
Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing
Collection Container/Tube: Red top (serum gel/SST are not acceptable)
Submission Container/Tube: Plastic vial
Specimen Volume: 3.5 mL Serum
Collection Instructions:
1. Within 45 minutes of collection, centrifuge and aliquot serum into a plastic vial.
2. Send frozen.
Additional Information: To avoid delays in turnaround time when requesting multiple tests, submit separate frozen specimens for each test requested.
Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the testing laboratory. The minimum volume is sufficient for one attempt at testing.
Serum: 2 mL Note: This volume does not allow for repeat testing.
Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Gross icteric | Reject |
Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum Red | Frozen | 90 days |
Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Refer to www.labcorp.com/test-menu/
Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Androstenedione:
Premature (26-28 weeks) Day 4: 63-935 ng/dL
Premature (31-35 weeks) Day 4: 50-449 ng/dL
Full Term (1-7 days): <10-279 ng/dL
Levels decrease rapidly to <52 ng/dL after one week.
1 month-11 months: <10-37 ng/dL
Androstenedione gradually decreases during the first six months to prepubertal levels.
Prepubertal Children: <10-17 ng/dL
Adults
Males: 44-186 ng/dL
Females: 2 -230 ng/dL
Females Postmenopausal: <10-93 ng/dL
Cortisol:
Premature (26-28 weeks) Day 4: 1.0-11 ug/dL
Premature (31-35 weeks) Day 4: 2.5-9.1 ug/dL
Full Term Day 3: 1.7-14 ug/dL
Full Term Day 7: 2.0-11 ug/dL
31 days-11 months: 2.8-23 ug/dL
12 months-15 years (8 a.m.): 3.0-21 ug/dL
Adults
8 a.m.: 8.0-19 ug/dL
4 p.m.: 4.0-11 ug/dL
Deoxycorticosterone (DOC):
Premature (26-28 weeks) Day 4: 20-105 ng/dL
Premature (34-36 weeks) Day 4: 28-78 ng/dLNewborn: Levels are markedly elevated at birth and decrease rapidly during the first week to the range of 7-49 ng/dL as found in older infants.
1 month-11 months: 7-49 ng/dL
Prepubertal Children: 2-34 ng/dL
Pubertal Children and Adults 8 a.m.: 2-19 ng/dL
Dehydroepiandrosterone (DHEA):
Premature (26-31 weeks): 82-1484 ng/dL
Premature (32-35 weeks): 56-1853 ng/dL
Full Term (2-7 days): 41-1292 ng/dL
8 days-5 months: <948 ng/dL
6 months-12 months: <136 ng/dL
1 year-5 years: <68 ng/dL
6-7 years: <111 ng/dL
8-10 years: <186 ng/dL
11-12 years: <202 ng/dL
13-14 years: <319 ng/dL
15-16 years: 39-481 ng/dL
17-19 years: 40-491 ng/dL
20-50 years: 31-701 ng/dL
>50 years: 21-402 ng/dL
11-Desoxycortisol:
Premature (26-28 weeks) Day 4: 110-1376 ng/dL
Premature (31-35 weeks) Day 4: 48-579 ng/dL
Full term Newborn Day 3: 13-147 ng/dL
1 month-11 months: <10-156 ng/dL
Prepubertal 8 a.m.: 20-155 ng/dL
Pubertal Children and Adults 8 a.m.: 12-158 ng/dL
17-OH Pregnenolone:
Premature (26-28 weeks) Day 4: 375-3559 ng/dL
Premature (31-35 weeks) Day 4: 64-2380 ng/dL
3 days: 10-829 ng/dL
1 month-5 months: 36-763 ng/dL
6-11 months: 42-540 ng/dL
12-23 months: 14-207 ng/dL
24 months-5 years: 10-103 ng/dL
6-9 years: 10-186 ng/dL
Pubertal: 44-235 ng/dL
Adults: 53-357 ng/dL
Progesterone:
Males
1 year-16 years: <10-15 ng/dL
Adults: <10-11 ng/dL
Females
1 year-10 years: <10-26 ng/dL
11 years: <10-255 ng/dL
12 years: <10-856 ng/dL
13 years: <10-693 ng/dL
14 years: <10-1204 ng/dL
15 years: <10-1076 ng/dL
16 years: <10-1294 ng/dL
Adult
Cycle days
1-6: <10-17 ng/dL
7-12: <10-135 ng/dL
13-15: <10-1563 ng/dL
16-28: <10-2555 ng/dL
Post Menopausal: <10 ng/dL
Note: Luteal progesterone peaked from 350 to 3750 ng/dL on days ranging from 17 to 23.
17-Alpha-Hydroxyprogesterone (17-OHP):
Premature (26-28 weeks) Day 4: 124-841 ng/dL
Premature (31-35 weeks) Day 4: 26-568 ng/dL
Full-Term Day 3: <78 ng/dL
Males:
Levels increase after the first week to peak values ranging from 40-200 ng/dL between 30 and 60 days. Values then decline to a prepubertal value of <91 ng/dL before one year.
Prepubertal: <91 ng/dL
Adult: 27-199 ng/dL
Females:
1 month-11 months: 13-106 ng/dL
Prepubertal: <91 ng/dL
Adult:
Follicular: 15-70 ng/dL
Luteal: 35-290 ng/dL
Testosterone, Total
Males:
Premature (26-28w) Day 4: 59-125 ng/dL
Premature (31-35w) Day 4: 37-198 ng/dL
Newborns: 75-400 ng/dL
1 month-7 months: Levels decrease rapidly the first week to 20-50 ng/dL, then increase to 60-400 ng/dL between 20 and 60 days. Levels then decline to prepubertal range levels of <2.5-10 ng/dL by seven months.
Females:
Premature (26-28w) Day 4: 5-16 ng/dL
Premature (31-35w) Day 4: 5-22 ng/dL
Newborns: 20-64 ng/dL
1 month-7 months: Levels decrease during the first month to less than 10 ng/mL and remain there until puberty.
Prepubertal Males and Females: <2.5-10 ng/dL
Adult
Males >18 years: 264-916 ng/dL
Females:
Premenopausal: 10-55 ng/dL
Postmenopausal: 7-40 ng/dL
Males
Tanner Stage 1 <9.8 years: <2.5-10 ng/mL
Tanner Stage 2 9.8 years-14.5 years: 18-150 ng/mL
Tanner Stage 3 10.7 years-15.4 years: 100-320 ng/mL
Tanner Stage 4 11.8 years-16.2 years: 200-620 ng/mL
Tanner Stage 5 12.8 years-17.3 years: 350-970 ng/mL
Females
Tanner Stage 1 <9.2 years: <2.5-10 ng/mL
Tanner Stage 2 9.2-13.7 years: 7-28 ng/mL
Tanner Stage 3 10.0-14.4 years: 15-35 ng/mL
Tanner Stage 4 10.7-15.6 years: 13-32 ng/mL
Tanner Stage 5 11.8-18.6 years: 20-38 ng/mL
PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information
Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.
Monday, Wednesday
Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.
Performing Laboratory Location
Indicates the location of the laboratory that performs the test
Fees :
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact Customer Service.
Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.
CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
CPT codes are provided by the performing laboratory.
CPT codes are provided by the performing laboratory.
82633 - DOC
82634 - 11-Desoxycortisol
82157 - Androstenedione
82533 - Cortisol
82626 - DHEA
84143 - 17-OH-Pregnenolone
84144 - Progesterone
83498 - 17-OH-Progesterone
84403 - Testosterone
LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.
| Test Id | Test Order Name | Order LOINC Value |
|---|---|---|
| FFCAH | CAH Profile 6 | Not Provided |
| Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
|---|---|---|
| Z5043 | Cortisol | 2143-6 |
| Z5044 | Deoxycorticosterone (DOC) | 1656-8 |
| Z5045 | 11-Desoxycortisol | 1657-6 |
| Z5046 | Dehydroepiandrosterone (DHEA) | 2193-1 |
| Z5047 | 17-OH Pregnenolone | 6765-2 |
| Z5048 | Progesterone | 2839-9 |
| Z5049 | 17-Alpha-Hydroxyprogesterone 17-OHP | 1668-3 |
| Z5050 | Androstenedione | 1854-9 |
| Z5051 | Testosterone, Total | 2986-8 |